PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
about
Recent advances in understanding antitumor immunityPD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.Clinical application of a cancer genomic profiling assay to guide precision medicine decisions.The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.DNA methylation/hydroxymethylation in melanoma.Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy.Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung CancerPredominance of triple wild-type and IGF2R mutations in mucosal melanomas
P2860
Q28067217-8FE6B5B8-D4C0-4B50-851E-D5C740FE14A0Q37718331-74A48F71-C183-4F30-9BC6-115E32F3ED29Q38611235-C33D1BB6-7114-4515-9840-93ED2ADACF34Q38759770-A8DC98F6-0FBF-4483-9176-9F81F170EB19Q38839124-5C708C8E-FBC1-4EC6-876D-5AB5CCF188E8Q40048521-0C4F3F21-4690-4805-B791-D59A473ADED7Q40357824-F50BB505-F826-42B0-9981-EDA888DBCEF6Q47119104-46722D61-C14B-4C20-9078-1A6E38378073Q47568875-E725BD0F-63C6-4879-99A0-FCCDB3E01030Q48703829-02D2D8BD-CD86-4A3D-9C9F-B9E43B6D6AA8Q52655048-C55091EE-73FF-4BBB-94E4-5A9C8E6FDDC0Q53068034-8F4222D6-D6D1-4727-A035-6CF7D4769994Q55376898-118B4D53-73C3-4D5E-9A28-B15CEC75221DQ57300289-F55A4441-0CDD-410D-A5CA-97426118E8B5Q58093307-B5EF51BA-9F33-4E33-A9F2-8B469A24CB35
P2860
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PD-L1 Negative Status is Assoc ...... urvival in Stage III Melanoma.
@en
PD-L1 Negative Status is Assoc ...... urvival in Stage III Melanoma.
@nl
type
label
PD-L1 Negative Status is Assoc ...... urvival in Stage III Melanoma.
@en
PD-L1 Negative Status is Assoc ...... urvival in Stage III Melanoma.
@nl
prefLabel
PD-L1 Negative Status is Assoc ...... urvival in Stage III Melanoma.
@en
PD-L1 Negative Status is Assoc ...... urvival in Stage III Melanoma.
@nl
P2093
P50
P1476
PD-L1 Negative Status is Assoc ...... urvival in Stage III Melanoma.
@en
P2093
Dario Strbenac
James S Wilmott
John F Thompson
Ricardo Vilain
P304
P356
10.1158/1078-0432.CCR-15-1714
P407
P577
2016-03-09T00:00:00Z